It is noteworthy that while JAK2 and MEK inhibitor combination therapy in MPN mouse models significantly reduced bone marrow fibrosis it did not enhance a reduction in mutant allele burden [65], but it is possible that longer time of therapeutic treatment (a limitation of MPN mouse models) may show some effect in this regard. Here, JAK2 is linked to myeloproliferative disorder.